-
Something wrong with this record ?
A non-radioactive assay for precise determination of intracellular levels of imatinib and its main metabolite in Bcr-Abl positive cells
P. Mlejnek, O. Novak, P. Dolezel
Language English Country England, Great Britain
Document type Journal Article, Research Support, Non-U.S. Gov't
Grant support
NR9482
MZ0
CEP Register
- MeSH
- Biological Assay methods MeSH
- K562 Cells MeSH
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive metabolism MeSH
- Humans MeSH
- Limit of Detection MeSH
- Piperazines chemistry metabolism MeSH
- Gas Chromatography-Mass Spectrometry MeSH
- Antineoplastic Agents chemistry metabolism MeSH
- Pyrimidines chemistry metabolism MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Multidrug resistance (MDR) is often associated with overexpression of the P-glycoprotein (P-gp, ABCB1). It was demonstrated that the P-gp mediated efflux decreases the drug concentration in cancer cells which results in the failure of chemotherapy. However, the MDR phenotype in cancer cells obviously involves various mechanisms. Therefore, if we want to estimate a contribution of the P-gp expression to the MDR phenotype, a clear quantitative relationship between the intracellular drug level and cell sensitivity must be established. To achieve this goal, a sensitive and non-radioactive assay for precise determination of intracellular levels of imatinib and its main metabolite N-desmethyl imatinib (CGP 74588) has been developed. The assay is based on an optimised extraction of cells with 4% formic acid after their separation from the growth medium by centrifugation through a layer of silicone oil. Cell extracts are subsequently analyzed by LC/MS/MS. Calibration curves were linear from 1 to 500 nmol/l for imatinib and from 2 to 500 nmol/l for CGP 74588, with correlation coefficients (r(2)) better than 0.998 and 0.996, respectively. The limit of quantitation (LOQ) was 1 nmol/l for imatinib and 2 nmol/l for CGP 74588. Our method has been successfully applied to the determination of intracellular levels of imatinib in sensitive K562 and their resistant variant, K562/Dox cells.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc12027124
- 003
- CZ-PrNML
- 005
- 20160417111903.0
- 007
- ta
- 008
- 120816s2011 enk f 000 0#eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.talanta.2010.11.028 $2 doi
- 035 __
- $a (PubMed)21238737
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Mlejnek, Petr, $d 1963- $7 xx0023808 $u Department of Biology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic. mlejnek petr@volny.cz
- 245 12
- $a A non-radioactive assay for precise determination of intracellular levels of imatinib and its main metabolite in Bcr-Abl positive cells / $c P. Mlejnek, O. Novak, P. Dolezel
- 520 9_
- $a Multidrug resistance (MDR) is often associated with overexpression of the P-glycoprotein (P-gp, ABCB1). It was demonstrated that the P-gp mediated efflux decreases the drug concentration in cancer cells which results in the failure of chemotherapy. However, the MDR phenotype in cancer cells obviously involves various mechanisms. Therefore, if we want to estimate a contribution of the P-gp expression to the MDR phenotype, a clear quantitative relationship between the intracellular drug level and cell sensitivity must be established. To achieve this goal, a sensitive and non-radioactive assay for precise determination of intracellular levels of imatinib and its main metabolite N-desmethyl imatinib (CGP 74588) has been developed. The assay is based on an optimised extraction of cells with 4% formic acid after their separation from the growth medium by centrifugation through a layer of silicone oil. Cell extracts are subsequently analyzed by LC/MS/MS. Calibration curves were linear from 1 to 500 nmol/l for imatinib and from 2 to 500 nmol/l for CGP 74588, with correlation coefficients (r(2)) better than 0.998 and 0.996, respectively. The limit of quantitation (LOQ) was 1 nmol/l for imatinib and 2 nmol/l for CGP 74588. Our method has been successfully applied to the determination of intracellular levels of imatinib in sensitive K562 and their resistant variant, K562/Dox cells.
- 650 _2
- $a protinádorové látky $x chemie $x metabolismus $7 D000970
- 650 _2
- $a biotest $x metody $7 D001681
- 650 _2
- $a plynová chromatografie s hmotnostně spektrometrickou detekcí $7 D008401
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a buňky K562 $7 D020014
- 650 _2
- $a chronická myeloidní leukemie $x metabolismus $7 D015464
- 650 _2
- $a limita detekce $7 D057230
- 650 _2
- $a piperaziny $x chemie $x metabolismus $7 D010879
- 650 _2
- $a pyrimidiny $x chemie $x metabolismus $7 D011743
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Novák, Ondřej $7 xx0120183 $u Laboratory of Growth Regulators, Faculty of Science, Palacky University and Institute of Experimental Botany ASCR, Slechtitelu 11, CZ-78371 Olomouc, Czech Republic
- 700 1_
- $a Doležel, Petr $7 xx0317513 $u Department of Biology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Hnevotinska 3, Olomouc 77515, Czech Republic
- 773 0_
- $w MED00004484 $t Talanta $x 1873-3573 $g Roč. 83, č. 5 (2011), s. 1466-71
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/21238737 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y m $z 0
- 990 __
- $a 20120816 $b ABA008
- 991 __
- $a 20160417111950 $b ABA008
- 999 __
- $a ok $b bmc $g 949166 $s 784470
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2011 $b 83 $c 5 $d 1466-71 $i 1873-3573 $m Talanta $n Talanta $x MED00004484
- GRA __
- $a NR9482 $p MZ0
- LZP __
- $b NLK122 $a Pubmed-20120816/11/02